HARBIN MEDISAN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.87 CNY | -1.60% |
|
-10.76% | -27.69% |
| 26/04 | Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023 | CI |
| 26/04 | Medisan Pharma's Potassium Chloride Injection Passes Drug Regulator's Evaluation | MT |
| Sales 2022 | 1.03B 142M 11.83B | Sales 2023 | 1.19B 164M 13.66B | Capitalization | 4.23B 584M 48.65B |
|---|---|---|---|---|---|
| Net income 2022 | 30M 4.14M 345M | Net income 2023 | 73M 10.07M 840M | EV / Sales 2022 | 3.49 x |
| Net cash position 2022 | 637M 87.94M 7.33B | Net cash position 2023 | 331M 45.62M 3.8B | EV / Sales 2023 | 3.28 x |
| P/E ratio 2022 |
137
x | P/E ratio 2023 |
56.9
x | Employees | 1,721 |
| Yield 2022 |
0.73% | Yield 2023 |
-
| Free-Float | 32.26% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.60% | ||
| 1 week | -10.76% | ||
| Current month | -2.08% | ||
| 1 month | -0.80% | ||
| 3 months | -16.92% | ||
| 6 months | -20.66% | ||
| Current year | -27.69% |
1 week
9.53
10.70
1 month
9.2814.40
Current year
6.7414.40
1 year
6.7415.49
3 years
6.7436.99
5 years
6.7436.99
10 years
6.7436.99
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Fei Qin
CEO | Chief Executive Officer | 61 | 24/13/24 |
Zhi Cheng Zhao
DFI | Director of Finance/CFO | 49 | 05/21/05 |
Dan Fei Liang
BRD | Director/Board Member | 57 | 24/13/24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fu Sheng Wang
BRD | Director/Board Member | 60 | 18/19/18 |
Hongquan Liu
BRD | Director/Board Member | 65 | 17/22/17 |
Jian Fei Qin
CEO | Chief Executive Officer | 61 | 24/13/24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 9.87 | -1.60% | 11,010,140 |
| 25/24/25 | 10.03 | +2.45% | 11,799,170 |
| 24/24/24 | 9.79 | -1.11% | 11,373,790 |
| 23/24/23 | 9.9 | -0.60% | 12,275,930 |
| 22/24/22 | 9.96 | -9.95% | 19,207,810 |
End-of-day quote Shenzhen S.E., April 26, 2024
More quotes
HARBIN MEDISAN PHARMACEUTICAL CO LTD is a China-based company principally engaged in the research and development, production and sales of chemical preparations, active pharmaceutical ingredients (APIs), medical devices and cosmetics. Its medicines cover the nervous system, cardio-cerebrovascular, systemic anti-infection, musculoskeletal, nutritional infusion, and body fluid balance infusion therapeutic fields. The Company's products include freeze-dried powder injections, small volume injections, large infusion products, solid preparations, medical devices and cosmetics. The Company mainly distributes its products within domestic market.
Sector
Pharmaceuticals
Calendar
16/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -27.69% | 422M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 002900 Stock
